Anchored in a proprietary drug-discovery-platform invented by firm's founders while previously with the firm Sunesis Pharmaceuticals and subsequently licensed from that Corporation, No longer SIR involved or associated, Carmot Therapeutics had been pioneering the discovery and development of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation superior drugs for challenging therapeutic targets. Chemotype Evolution, Carmots proprietary technology, enabled the rapid identification of novel drugs through an evolutionary discovery paradigm and produced a pipeline of breakthrough therapeutics currently in pre-clinical development. SInce the founding of Carmot, the firm built Chemotype Evolution into a robust technology that has yielded novel lead compounds targeting incretin receptors (GLP-1R and GIPR) for treatment of Type 2 diabetes, obesity, and NASH and protein-protein interactions (NEMO/IKK) for treatment of cancer and inflammation. Consistent with the idea of collaborating with industry partners to apply Chemotype Evolution to targets of mutual interest, in 2014, Carmot entered into a collaboration with Amgen to apply Chemotype Evolution to two difficult, high value targets and in 2016, Carmot extended the collaboration with Amgen and entered into a new drug discovery collaboration and license agreement with Genentech.Headquartered in Berkeley, the firm has facilities also in San Francisco.
